Balyasny Asset Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-245,191
| Closed | -$22.8M | – | 3047 |
|
|
2021
Q4 | $22.8M | Buy |
+245,191
| New | +$16.2M | 0.08% | 357 |
|
|
2020
Q2 | – | Sell |
-5,800
| Closed | -$244K | – | 1604 |
|
|
2020
Q1 | $244K | Buy |
5,800
+142
| +3% | +$6.51K | ﹤0.01% | 1027 |
|
|
2019
Q4 | $257K | Buy |
+5,658
| New | +$267K | ﹤0.01% | 1082 |
|
|
2019
Q3 | – | Sell |
-25,692
| Closed | -$1.51M | – | 1733 |
|
|
2019
Q2 | $1.51M | Buy |
+25,692
| New | +$1.33M | 0.01% | 967 |
|
|
2019
Q1 | – | Sell |
-9,179
| Closed | -$358K | – | 1751 |
|
|
2018
Q4 | $358K | Sell |
9,179
-164,575
| -95% | -$6.46M | ﹤0.01% | 1181 |
|
|
2018
Q3 | $8M | Buy |
173,754
+1,458
| +0.8% | +$59.1K | 0.04% | 556 |
|
|
2018
Q2 | $7.51M | Sell |
172,296
-901,580
| -84% | -$38.7M | 0.03% | 567 |
|
|
2018
Q1 | $42.4M | Sell |
1,073,876
-75,953
| -7% | -$2.95M | 0.18% | 151 |
|
|
2017
Q4 | $39.1M | Buy |
1,149,829
+98,235
| +9% | +$2.8M | 0.12% | 216 |
|
|
2017
Q3 | $26.8M | Buy |
1,051,594
+329,415
| +46% | +$7.56M | 0.11% | 259 |
|
|
2017
Q2 | $12.2M | Buy |
+722,179
| New | +$9.9M | 0.05% | 478 |
|
|
2017
Q1 | – | Sell |
-72,500
| Closed | -$1.03M | – | 1847 |
|
|
2016
Q4 | $1.03M | Buy |
+72,500
| New | +$1.12M | 0.01% | 1017 |
|
Balyasny Asset Management's ARNA Position: Q1 2022 in Review
Balyasny Asset Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 245,191 shares — an estimated $22.8M sold.
Balyasny Asset Management first reported a position in ARNA in Q4 2016 and held it in 12 quarters. The position peaked at $42.4M in Q1 2018. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Balyasny Asset Management reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Balyasny Asset Management sold 245,191 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $22.8M.
- Balyasny Asset Management first reported a position in Arena Pharmaceuticals Inc in Q4 2016 and held it in 12 quarters.
- Balyasny Asset Management's Arena Pharmaceuticals Inc position peaked at $42.4M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Balyasny Asset Management's 13F filing for Q1 2022, filed 16 May 2022.